Emerging preclinical evidence does not support broad use of hydroxychloroquine in COVID-19 patients
There is an urgent need for drugs, therapies and vaccines to be available to protect the human population against COVID-19. One of the first approaches taken in the COVID-19 global response was to consider repurposing licensed drugs. This commentary highlights an extraordinary international collabor...
Guardado en:
Autores principales: | S. G. P. Funnell, W. E. Dowling, C. Muñoz-Fontela, P.-S. Gsell, D. E. Ingber, G. A. Hamilton, L. Delang, J. Rocha-Pereira, S. Kaptein, K. H. Dallmeier, J. Neyts, K. Rosenke, E. de Wit, H. Feldmann, P. Maisonnasse, R. Le Grand, M. B. Frieman, C. M. Coleman |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/16f0fbaa1ef74b81ae8f7a0d0a46c7fa |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells.
por: Marijke M F Alen, et al.
Publicado: (2011) -
Hydroxychloroquine in COVID-19: The Study Points to Premature Decisions on Efficacy While Bells Ringing for Safety
por: Khadka S, et al.
Publicado: (2020) -
A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite
por: Laura-Oana Albulescu, et al.
Publicado: (2020) -
Author Correction: A therapeutic combination of two small molecule toxin inhibitors provides broad preclinical efficacy against viper snakebite
por: Laura-Oana Albulescu, et al.
Publicado: (2021) -
Hydroxychloroquine in IgA nephropathy: a systematic review
por: Gabriel Stefan, et al.
Publicado: (2021)